Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263613 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01263613 is a Early Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 6 participants.
The verdict
NCT01263613, a Early Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the investigators are able to locate and measure certain characteristics in breast cancer tumors that have been treated with paclitaxel that may correlate to how well the cancer will respond to the chemotherapy.
Interventions
- PROCEDURE tumor biopsy and blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263613
The ClinicalTrials.gov registry entry for NCT01263613 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tumor biopsy and blood draw is the first listed.
NCT01263613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01263613 about?
NCT01263613 is a clinical study titled "Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer". The purpose of this study is to determine if the investigators are able to locate and measure certain characteristics in breast cancer tumors that have been treated with paclitaxel that may correlate to how well the cancer will respond to the chemotherapy.
What is the current status of trial NCT01263613?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2010-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01263613?
The interventions under investigation include: tumor biopsy and blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT01263613?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.